The global external pacemakers market is anticipated to grow at a CAGR of 3.6% during the forecast period (2023-2030). The key factors for the promising growth of global external pacemakers market are increasing number of patients undergoing stroke, technological advancements, enhancement in health facilities, rising healthcare investments, and increasing change in lifestyle related diseases such as obesity which is the major cause of increasing stroke incidences. According to the World Stroke Organization (WSO) 2022, there are 12.2 million new strokes per year one every 3 seconds around the globe. There are 101 million people around the globe are living with stroke aftermath. this number has almost doubled over the last 30 years. Further, 1 in 4 people will have a stroke in their lifetime this number has increased 50% over the last 17 years. Up to 80 of strokes and heart attacks happen in people with 63.0% low or moderate cardiovascular diseases (CVD) absolute risk. In 2019, 63.0% of stroke happened in people younger aged below 70 years. In addition, the rising number of FDA approval also bolstering the external pacemakers market growth.
Browse the full report description of “External Pacemakers Market Size, Share & Trends Analysis Report by Type (MRI Compatible Pacemaker, and Conventional Pacemaker), by Technology (Single-chamber Pacemaker, Dual-chamber Pacemaker, and Biventricular/CRT Pacemaker), by Application, (Bradycardia, and Acute Myocardial Infarction), and by End-Use (Hospitals & Cardiac Centers, and Ambulatory Surgical Centers), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/external-pacemakers-market
• In May 2023, Medtronic plc, a pioneer in healthcare technology, received US Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers. Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.
• In July 2023, Abbott Laboratories received the US Food and Drug Administration (FDA) approval the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Technology
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Abbott Laboratories, Boston Scientific Corp., Medtronic plc, Xerox Holdings Corp., BIOTRONIK SE & Co KG, Fluke Corp., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global External Pacemakers Market Report Segment
By Type
By Technology
By Application
By End-User
Global External Pacemakers Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/external-pacemakers-market